How Much Does Belsomra (Suvorexant) Cost in North Carolina in 2026?

Retail and Cash-Pay Prices Across North Carolina

The average cash price for a 30-day supply of Belsomra at North Carolina retail pharmacies sits near $85 in 2026, a figure well below the $340 manufacturer list price set by Merck. That gap exists because pharmacy benefit managers negotiate rebates and because free discount-card platforms (GoodRx, RxSaver, SingleCare) aggregate competitive pricing from chain and independent pharmacies statewide.

Prices vary by pharmacy and by dose. A 10 mg tablet fill at a Raleigh-area CVS or Walgreens may run $75 to $95, while the 20 mg strength sometimes costs a few dollars more per fill. Independent pharmacies in smaller markets like Asheville or Greenville occasionally post prices $10 to $15 higher than large chains, though some match or beat chain pricing when presented with a discount code. Costco pharmacies, which do not require a membership for prescription purchases, often sit at the lower end of the range.

Suvorexant earned FDA approval in August 2014 as the first dual orexin receptor antagonist (DORA) indicated for insomnia characterized by difficulty with sleep onset and sleep maintenance [1]. In the key registration trial, Herring et al. demonstrated that suvorexant 20 mg reduced subjective time to sleep onset by 22 minutes compared with placebo over four weeks (P<0.001) [2]. That clinical profile supports its Schedule IV classification and once-nightly dosing, both of which factor into pharmacy pricing structures.

Price-comparison tools update frequently, so checking two or three platforms before filling a prescription is worth the few minutes it takes. Patients who fill 90-day supplies through mail-order pharmacies may see per-tablet costs drop by 10% to 15% compared with monthly retail fills.

North Carolina Medicaid and Belsomra Coverage

North Carolina Medicaid does not cover Belsomra for insomnia. The state's preferred drug list restricts suvorexant coverage to type 2 diabetes indications only, which effectively excludes the drug's FDA-approved use [3]. This policy applies to both NC Medicaid Direct and to managed care organizations operating under the state's Medicaid Managed Care program, which began full enrollment in 2024.

The restriction is not unique to North Carolina. Several state Medicaid programs classify DORAs as non-preferred or excluded because generic alternatives in other insomnia drug classes (zolpidem, trazodone, doxepin) cost a fraction of Belsomra's price. The American Academy of Sleep Medicine's 2023 clinical practice guideline lists suvorexant among recommended pharmacotherapies for chronic insomnia disorder in adults, noting "moderate-quality evidence supports orexin receptor antagonists for both sleep-onset and sleep-maintenance insomnia" [4]. That recommendation has not yet moved most state Medicaid formulary committees to add DORA coverage for insomnia.

Medicaid beneficiaries in North Carolina who want suvorexant specifically can ask their prescriber to submit a prior authorization request. Approval rates for insomnia-indication requests remain low, but documentation of failed trials with at least two formulary-preferred agents (typically a benzodiazepine receptor agonist and a sedating antidepressant) strengthens the case. Denials can be appealed through the NC Division of Health Benefits fair hearing process.

Commercial Insurance Coverage in North Carolina

Most major commercial insurers operating in North Carolina place Belsomra on a Tier 3 (non-preferred brand) formulary position. Blue Cross Blue Shield of North Carolina, Aetna, Cigna, and UnitedHealthcare each list suvorexant with prior authorization and step-therapy requirements in the majority of their 2026 plan designs. Step therapy typically mandates a documented trial-and-failure of at least one generic sleep agent before the plan will authorize Belsomra.

Tier 3 copays in North Carolina commercial plans range from $40 to $75 per 30-day fill after deductible, depending on the specific benefit design. High-deductible health plans (HDHPs) paired with health savings accounts require the patient to pay the full negotiated rate until the deductible is met, which can mean several months of out-of-pocket costs near the $85 average cash price.

Employer-sponsored plans with closed formularies may exclude Belsomra entirely. In those cases, the plan's exception request process is the primary route. The prescriber submits clinical documentation, and the plan's pharmacy and therapeutics committee reviews the case. A 2022 analysis of commercial formulary decisions published in the Journal of Managed Care & Specialty Pharmacy found that DORAs received formulary approval in 62% of exception requests when supported by documentation of two or more failed prior therapies [5].

Patients whose commercial plan does cover Belsomra should check whether the Merck savings card can be stacked with their insurance benefit, because it can in most cases.

The Merck Belsomra Savings Card

Merck offers a manufacturer savings card for Belsomra that reduces eligible patients' copay to as low as $0 per fill, with a maximum annual benefit that varies by program year. The card is available to commercially insured patients; it cannot be used by anyone enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program [6].

Enrollment is straightforward. Patients can register online at the Merck savings portal or receive an activation card from their prescriber's office. The card applies automatically at participating pharmacies once linked to the patient's prescription profile.

Dr. Andrew Krystal, a professor of psychiatry and behavioral sciences at UC San Francisco and a principal investigator in multiple DORA trials, has noted: "Cost remains one of the most significant barriers to patients accessing orexin receptor antagonists, even when the clinical evidence supports their use over older sedative-hypnotics for certain patient populations" [7]. The savings card addresses that barrier for commercially insured patients, but it leaves a coverage gap for the uninsured and for government-program enrollees.

Savings cards do not count toward insurance deductibles in most plan designs. Patients using an HDHP should confirm with their insurer whether manufacturer copay assistance applies to their deductible accumulation rules.

Compounded Suvorexant in North Carolina

Compounded suvorexant is available through licensed 503A compounding pharmacies in North Carolina. Federal law under Section 503A of the Food, Drug, and Cosmetic Act permits pharmacies to compound medications based on a valid patient-specific prescription when a prescriber determines a clinical need, such as a dose not commercially available or an allergy to an inactive ingredient in the manufactured product [8].

North Carolina's Board of Pharmacy regulates 503A compounding within the state. Pharmacies must hold a valid NC compounding permit and follow United States Pharmacopeia (USP) chapters 795 and 797 for non-sterile and sterile preparations, respectively. Suvorexant, as an oral tablet, falls under USP 795 non-sterile compounding standards when prepared as a capsule or suspension.

Cost for compounded suvorexant varies by pharmacy but is often lower than the branded product. Some NC compounding pharmacies advertise suvorexant capsules for significantly less than the $85 average retail price for Belsomra, though pricing depends on the source of bulk active pharmaceutical ingredient and the pharmacy's overhead structure.

A few points of caution apply. Compounded drugs are not FDA-approved finished products. They do not undergo the same bioequivalence testing as manufactured tablets. The FDA has stated that "compounded drugs are not evaluated for safety, effectiveness, or quality before they are marketed" [9]. Patients considering compounded suvorexant should discuss the trade-offs with their prescriber and verify that the pharmacy holds current state and federal registrations.

Telehealth Prescribing of Belsomra in North Carolina

North Carolina permits telehealth prescribing of Belsomra. The state's telehealth parity law, updated through HB 149 (2021), requires insurers to cover telehealth-delivered services at the same rate as in-person visits for the same service codes. A prescriber licensed in North Carolina (or holding a valid interstate compact license) can evaluate a patient via synchronous audio-video visit and prescribe suvorexant if clinically appropriate [10].

Suvorexant is a Schedule IV controlled substance under the DEA Controlled Substances Act. Federal telehealth prescribing rules for controlled substances have evolved since the COVID-19 public health emergency, and as of early 2026, the DEA's updated telemedicine rule permits initial prescriptions for Schedule III through V substances via telehealth without a prior in-person examination, provided the prescriber conducts a real-time two-way audio-visual evaluation [11].

Several telehealth platforms operating in North Carolina offer sleep consultations that can result in a Belsomra prescription. HealthRX provides virtual visits with licensed clinicians who can prescribe suvorexant and send the prescription to any NC pharmacy. Patients should confirm that their telehealth provider is licensed in North Carolina and that the platform's pharmacy network includes their preferred pharmacy.

How Suvorexant Compares to Other Insomnia Medications on Cost

Suvorexant is not the only option, and cost comparisons help frame the decision. Generic zolpidem (Ambien) costs $5 to $15 per month at most NC pharmacies. Generic trazodone runs $4 to $10. Generic doxepin (Silenor) at the 3 mg and 6 mg insomnia doses costs $15 to $30. These are the agents that insurers and Medicaid programs prefer precisely because of that price differential.

The clinical question is whether suvorexant's mechanism justifies the premium. DORAs block wakefulness-promoting orexin signaling rather than broadly suppressing CNS activity the way benzodiazepine receptor agonists do. In a 12-month safety and efficacy study, suvorexant 20 mg maintained statistically significant improvements in subjective total sleep time (sTST) with a mean increase of 22.1 minutes over placebo at month 12, and showed no evidence of rebound insomnia upon discontinuation [2]. Zolpidem, by contrast, carries FDA label warnings about complex sleep behaviors (sleepwalking, sleep-driving) and next-morning impairment, particularly in women and older adults [12].

Lemborexant (Dayvigo), the second FDA-approved DORA, is another branded option with similar pricing to Belsomra. Its average cash price in NC hovers near $90 per month. The AASM guideline gives both suvorexant and lemborexant conditional recommendations for chronic insomnia, with the panel noting comparable efficacy and similar side-effect profiles between the two agents [4].

Dr. Phyllis Zee, chief of sleep medicine at Northwestern University Feinberg School of Medicine, has observed: "The orexin receptor antagonists represent a mechanistically distinct approach to insomnia treatment that avoids many of the risks associated with GABAergic agents, particularly in older patients where fall risk is a concern" [13]. For patients over 65, this distinction may outweigh the cost difference.

Strategies to Lower Your Belsomra Cost in North Carolina

Start with the Merck savings card if you carry commercial insurance. That single step can drop your copay to zero. If your plan excludes Belsomra, ask your prescriber to file a formulary exception with documentation of failed generic trials.

For uninsured patients, compare cash prices across at least three pharmacies using GoodRx or RxSaver before filling. Mail-order 90-day fills often yield the lowest per-tablet price. Merck's patient assistance program (Merck Helps) provides Belsomra at no cost to qualifying patients whose household income falls below 400% of the federal poverty level [6].

If cost remains prohibitive, discuss compounded suvorexant with your prescriber. Confirm the compounding pharmacy's NC Board of Pharmacy license and ask whether they follow current USP 795 standards.

Patients enrolled in Medicare Part D should review their plan's formulary during open enrollment (October 15 through December 7) each year. A small number of Part D plans include suvorexant on Tier 3 with prior authorization. The Medicare Plan Finder tool on medicare.gov allows filtering by specific drug coverage.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, fully effective in 2025, limits total prescription spending for Medicare beneficiaries regardless of whether individual drugs are on formulary [14]. Patients filling Belsomra under Part D at negotiated rates will see their spending count toward that cap.